Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dysregulated Intraocular Pressure in Acanthamoeba Keratitis: Clinical Associations, Therapy, and Prognosis.

Microorganisms·2026
Same author

Sustainability awareness among European dry eye disease specialists.

European journal of ophthalmology·2026
Same author

Klinische Monatsblatter fur Augenheilkunde·2026
Same author

Corneal Allogeneic Intrastromal Ring Segments (CAIRS): Indications, Mechanism of Action and Outcomes.

Klinische Monatsblatter fur Augenheilkunde·2026
Same author

[Adjuvant Crosslinking to Improve Graft Survival after High-Risk Keratoplasty - A Case Series from the CrossCornealVision Study].

Klinische Monatsblatter fur Augenheilkunde·2026
Same author

Prevalence of anterior corneal scars impairing visual acuity after Descemet membrane endothelial keratoplasty (DMEK) and treatment by phototherapeutic keratectomy (PTK).

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2026

Related Experiment Video

Updated: Jul 6, 2025

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases
11:08

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases

Published on: June 22, 2012

16.0K

Preserflo MicroShunt: Efficacy and Endothelial Cell Density.

Friedrich Anton Steindor1, Céline Trigaux, Christoph Holtmann

  • 1Department of Ophthalmology, University of Düsseldorf, Düsseldorf, Germany.

Journal of Glaucoma
|January 11, 2024
PubMed
Summary

The Preserflo MicroShunt effectively lowers intraocular pressure in glaucoma patients. This study found no significant corneal endothelial cell loss (ECL) after implantation, indicating good corneal safety.

More Related Videos

Parallel-plate Flow Chamber and Continuous Flow Circuit to Evaluate Endothelial Progenitor Cells under Laminar Flow Shear Stress
12:43

Parallel-plate Flow Chamber and Continuous Flow Circuit to Evaluate Endothelial Progenitor Cells under Laminar Flow Shear Stress

Published on: January 17, 2012

43.4K
Intraluminal Drug Delivery to the Mouse Arteriovenous Fistula Endothelium
05:53

Intraluminal Drug Delivery to the Mouse Arteriovenous Fistula Endothelium

Published on: March 4, 2016

9.4K

Related Experiment Videos

Last Updated: Jul 6, 2025

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases
11:08

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases

Published on: June 22, 2012

16.0K
Parallel-plate Flow Chamber and Continuous Flow Circuit to Evaluate Endothelial Progenitor Cells under Laminar Flow Shear Stress
12:43

Parallel-plate Flow Chamber and Continuous Flow Circuit to Evaluate Endothelial Progenitor Cells under Laminar Flow Shear Stress

Published on: January 17, 2012

43.4K
Intraluminal Drug Delivery to the Mouse Arteriovenous Fistula Endothelium
05:53

Intraluminal Drug Delivery to the Mouse Arteriovenous Fistula Endothelium

Published on: March 4, 2016

9.4K

Area of Science:

  • Ophthalmology
  • Glaucoma Surgery
  • Corneal Safety

Background:

  • Corneal endothelial cell loss (ECL) is a primary safety concern for new glaucoma implants.
  • Even established procedures can lead to ECL.

Purpose of the Study:

  • To evaluate the efficacy of the Preserflo MicroShunt.
  • To assess the corneal safety, specifically ECL, following Preserflo MicroShunt implantation.

Main Methods:

  • A monocentric, prospective clinical observational study.
  • 14 eyes of 12 patients underwent Preserflo MicroShunt implantation.
  • Follow-up of at least 12 months, analyzing endothelial cell density (ECD), shunt tip-to-cornea distance, and surgical success.

Main Results:

  • Significant intraocular pressure reduction (8.2 mm Hg, P=0.0041) after a mean follow-up of 20 months.
  • No statistically significant reduction in preoperative vs. follow-up ECD (P=0.42).
  • Revision surgery was needed in 28.6% of patients.

Conclusions:

  • Preserflo MicroShunt effectively lowers intraocular pressure.
  • The device demonstrated good corneal safety, with no substantial ECL observed after a minimum follow-up of 17 months.